1National Cancer Control Institute, National Cancer Center, Goyang, Korea
2Department of Cancer Control and Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea
Copyright © 2020 by the Korean Cancer Association
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Characteristic | Total (n=1,000) | Men (n=501, 50.1%) | Women (n=499, 49.9%) | p-valuea) |
---|---|---|---|---|
Age (yr) | ||||
20-29 | 167 (16.7) | 89 (17.8) | 78 (15.6) | 0.840 |
30-39 | 188 (18.8) | 95 (19.0) | 93 (18.6) | |
40-49 | 216 (21.6) | 110 (22.0) | 106 (21.2) | |
50-59 | 209 (20.9) | 105 (21.0) | 104 (20.8) | |
60-69 | 206 (20.6) | 95 (19.0) | 111 (22.2) | |
≥ 70 | 14 (1.4) | 7 (1.4) | 7 (1.4) | |
Marital status | ||||
Married | 704 (70.4) | 333 (66.5) | 371 (74.3) | < 0.001 |
Widowed | 32 (3.2) | 8 (1.6) | 24 (4.8) | |
Divorced/Separated | 34 (3.4) | 18 (3.6) | 16 (3.2) | |
Single | 230 (23.0) | 142 (28.3) | 88 (17.6) | |
Education | ||||
Middle school or lower | 88 (8.8) | 30 (6.0) | 58 (11.6) | 0.002 |
High school | 422 (42.2) | 206 (41.1) | 216 (43.3) | |
College or higher | 490 (49.0) | 265 (52.9) | 225 (45.1) | |
Income (million KRW/mo) | ||||
≤ 0.99 | 119 (11.9) | 36 (7.2) | 83 (16.6) | < 0.001 |
1-1.99 | 147 (14.7) | 36 (7.2) | 111 (22.2) | |
2-2.99 | 229 (22.9) | 126 (25.1) | 103 (20.6) | |
3-3.99 | 241 (24.1) | 148 (29.5) | 93 (18.6) | |
4-4.99 | 150 (15.0) | 91 (18.2) | 59 (11.8) | |
≥ 5 | 114 (11.4) | 64 (12.8) | 50 (10.0) | |
Economic activity | ||||
Employed | 751 (75.1) | 455 (90.8) | 296 (59.3) | < 0.001 |
Housewife | 180 (18.0) | 0 | 180 (36.1) | |
Student | 39 (3.9) | 26 (5.2) | 13 (2.6) | |
Not employed | 30 (3.0) | 20 (4.0) | 10 (2.0) |
Cancer type |
Men |
Women |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Least fearful cancer |
Most fearful cancer |
Least fearful cancer |
Most fearful cancer |
|||||||||
Men’s response | Women’s response | p-valuea) | Men’s response | Women’s response | p-value | Men’s response | Women’s response | p-value | Men’s response | Women’s response | p-value | |
Stomach | 1.24±1.23 | 0.92±1.16 | < 0.001 | 0.45±0.97 | 0.37±0.83 | 0.160 | 0.97±1.16 | 0.94±1.14 | 0.743 | 0.83±1.15 | 0.93±1.15 | 0.185 |
Colon | 0.46±0.93 | 0.36±0.83 | 0.084 | 0.82±1.08 | 0.80±1.07 | 0.760 | 0.24±0.69 | 0.13±0.53 | 0.005 | 0.53±0.97 | 0.42±0.89 | 0.045 |
Lung | 0.21±0.67 | 0.26±0.71 | 0.245 | 1.43±1.27 | 1.41±1.26 | 0.877 | 0.16±0.59 | 0.14±0.54 | 0.724 | 0.82±1.14 | 0.54±0.99 | < 0.001 |
Liver | 0.26±0.70 | 0.29±0.71 | 0.573 | 1.02±1.13 | 0.98±1.10 | 0.609 | 0.10±0.43 | 0.13±0.55 | 0.228 | 0.41±0.84 | 0.35±0.77 | 0.279 |
Thyroid | 1.32±1.25 | 1.09±1.24 | 0.004 | 0.07±0.39 | 0.05±0.38 | 0.367 | 1.98±1.17 | 1.45±1.31 | < 0.001 | 0.06±0.34 | 0.16±0.61 | 0.002 |
Prostate | 1.09±1.16 | 1.26±1.27 | 0.028 | 0.37±0.86 | 0.38±0.91 | 0.782 | - | - | - | - | - | - |
Bladder | 0.46±0.87 | 0.51±0.94 | 0.405 | 0.05±0.30 | 0.07±0.42 | 0.336 | 0.34±0.76 | 0.36±0.78 | 0.704 | 0.05±0.34 | 0.08±0.39 | 0.228 |
Renal | 0.28±0.71 | 0.40±0.84 | 0.014 | 0.13±0.51 | 0.17±0.58 | 0.216 | 0.32±0.79 | 0.27±0.66 | 0.200 | 0.08±0.34 | 0.14±0.53 | 0.017 |
Pancreatic | 0.10±0.43 | 0.18±0.61 | 0.011 | 1.04±1.17 | 0.94±1.18 | 0.170 | 0.08±0.37 | 0.06±0.33 | 0.366 | 0.83±1.17 | 0.57±0.94 | < 0.001 |
Bile duct and gallbladder | 0.35±0.78 | 0.46±0.84 | 0.025 | 0.17±0.56 | 0.22±0.66 | 0.193 | 0.25±0.65 | 0.26±0.71 | 0.799 | 0.11±0.44 | 0.20±0.66 | 0.010 |
Leukemia | 0.17±0.62 | 0.19±0.63 | 0.710 | 0.29±0.77 | 0.34±0.85 | 0.318 | 0.13±0.53 | 0.13±0.55 | 0.965 | 0.44±0.92 | 0.46±0.96 | 0.760 |
Breast | 0.03±0.24 | 0.05±0.32 | 0.214 | 0.20±0.22 | 0.44±0.34 | 0.186 | 0.57±0.94 | 0.85±1.13 | < 0.001 | 0.66±1.07 | 0.82±1.20 | 0.024 |
Cervical | - | - | - | - | - | - | 0.52±0.93 | 0.81±1.12 | < 0.001 | 0.49±0.97 | 0.57±1.03 | 0.207 |
Uterine (endometrial) | - | - | - | - | - | - | 0.29±0.71 | 0.40±0.82 | 0.020 | 0.59±1.01 | 0.64±1.04 | 0.503 |
Ovarian | - | - | - | - | - | - | 0.13±0.49 | 0.26±0.69 | 0.001 | 0.44±0.91 | 0.63±1.05 | 0.002 |
Side effect | Men | Women | p-valuea) |
---|---|---|---|
Pain | 2.07±1.20 | 2.10±1.14 | 0.703 |
Fatigue | 0.49±0.90 | 0.57±0.99 | 0.169 |
General weakness | 0.66±0.93 | 0.82±1.01 | 0.011 |
Digestive dysfunction | 0.58±0.91 | 0.65±0.95 | 0.259 |
Sexual dysfunction | 0.23±0.64 | 0.08±0.40 | < 0.001 |
Psychological problems | 0.83±1.08 | 0.85±1.07 | 0.776 |
Urological dysfunction | 0.21±0.66 | 0.09±0.39 | 0.001 |
Motor dysfunction | 0.10±0.44 | 0.09±0.42 | 0.780 |
Sensory dysfunction | 0.16±0.53 | 0.19±0.62 | 0.500 |
Appearance change | 0.41±0.82 | 0.44±0.86 | 0.525 |
Lymphedema | 0.24±0.73 | 0.11±0.45 | 0.001 |
Infertility | 0.01±0.16 | 0.02±0.17 | 0.842 |
Characteristic | Total (n=1,000) | Men (n=501, 50.1%) | Women (n=499, 49.9%) | p-value |
---|---|---|---|---|
Age (yr) | ||||
20-29 | 167 (16.7) | 89 (17.8) | 78 (15.6) | 0.840 |
30-39 | 188 (18.8) | 95 (19.0) | 93 (18.6) | |
40-49 | 216 (21.6) | 110 (22.0) | 106 (21.2) | |
50-59 | 209 (20.9) | 105 (21.0) | 104 (20.8) | |
60-69 | 206 (20.6) | 95 (19.0) | 111 (22.2) | |
≥ 70 | 14 (1.4) | 7 (1.4) | 7 (1.4) | |
Marital status | ||||
Married | 704 (70.4) | 333 (66.5) | 371 (74.3) | < 0.001 |
Widowed | 32 (3.2) | 8 (1.6) | 24 (4.8) | |
Divorced/Separated | 34 (3.4) | 18 (3.6) | 16 (3.2) | |
Single | 230 (23.0) | 142 (28.3) | 88 (17.6) | |
Education | ||||
Middle school or lower | 88 (8.8) | 30 (6.0) | 58 (11.6) | 0.002 |
High school | 422 (42.2) | 206 (41.1) | 216 (43.3) | |
College or higher | 490 (49.0) | 265 (52.9) | 225 (45.1) | |
Income (million KRW/mo) | ||||
≤ 0.99 | 119 (11.9) | 36 (7.2) | 83 (16.6) | < 0.001 |
1-1.99 | 147 (14.7) | 36 (7.2) | 111 (22.2) | |
2-2.99 | 229 (22.9) | 126 (25.1) | 103 (20.6) | |
3-3.99 | 241 (24.1) | 148 (29.5) | 93 (18.6) | |
4-4.99 | 150 (15.0) | 91 (18.2) | 59 (11.8) | |
≥ 5 | 114 (11.4) | 64 (12.8) | 50 (10.0) | |
Economic activity | ||||
Employed | 751 (75.1) | 455 (90.8) | 296 (59.3) | < 0.001 |
Housewife | 180 (18.0) | 0 | 180 (36.1) | |
Student | 39 (3.9) | 26 (5.2) | 13 (2.6) | |
Not employed | 30 (3.0) | 20 (4.0) | 10 (2.0) |
Cancer type | Men |
Rank difference |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5-Year relative survival rate (rank) (A) | Least fearful cancer (rank) |
Most fearful cancer (rank) |
5-Year relative survival rate (rank) (F) | Least fearful cancer (rank) |
Most fearful cancer (rank) |
|||||||||||
Me (B) | Assuming I am a woman (C) | Me (D) | Assuming I am a woman (E) | Me (G) | Assuming I am a woman (H) | Me (I) | Assuming I am a woman (J) | B-A | G-F | C-G | E-I | H-B | J-D | |||
Stomach | 7 | 2 | 2 | 5 | 1 | 6 | 2 | 3 | 1 | 6 | –5 | –4 | 0 | 0 | 1 | 1 |
Colon | 6 | 5 | 12 | 4 | 9 | 7 | 9 | 7 | 6 | 4 | –1 | 2 | 3 | 3 | 2 | 0 |
Lung | 11 | 9 | 10 | 1 | 7 | 11 | 10 | 9 | 3 | 1 | –2 | –1 | 0 | 4 | 0 | 0 |
Liver | 9 | 8 | 11 | 3 | 10 | 12 | 13 | 8 | 10 | 2 | –1 | 1 | –2 | 0 | 0 | –1 |
Thyroid | 1 | 1 | 1 | 10 | 12 | 1 | 1 | 2 | 13 | 11 | 0 | 0 | 0 | –1 | 1 | 1 |
Prostate | 2 | 3 | - | 6 | - | - | - | 1 | - | 5 | 1 | - | - | - | –2 | –1 |
Bladder | 5 | 4 | 6 | 11 | 14 | 8 | 5 | 4 | 14 | 10 | –1 | –3 | 1 | 0 | 0 | –1 |
Renal | 4 | 7 | 7 | 9 | 13 | 4 | 6 | 6 | 12 | 9 | 3 | 2 | 1 | 1 | –1 | 0 |
Pancreatic | 12 | 11 | 14 | 2 | 6 | 14 | 14 | 11 | 2 | 3 | –1 | 0 | 0 | 4 | 0 | 1 |
Bile duct and gallbladder (tie) | 10 | 6 | 8 (tie) | 8 | 11 | 13 | 8 | 5 | 11 | 8 | –4 | –5 | 0 | 0 | –1 | 0 |
Leukemia | 8 | 10 | 13 | 7 | 8 | 10 | 12 | 10 | 8 | 7 | 2 | 2 | 1 | 0 | 0 | 0 |
Breast | 3 | 12 | 3 | 12 | 2 | 2 | 3 | 12 | 4 | 12 | 9 | 1 | 0 | –2 | 0 | 0 |
Cervical | - | - | 4 | - | 5 | 5 | 4 | - | 7 | - | - | –1 | 0 | –2 | - | - |
Uterine (endometrial) | - | - | 5 | - | 3 | 3 | 7 | - | 5 | - | - | 4 | –2 | –2 | - | - |
Ovarian | - | - | 8 (tie) | - | 4 | 9 | 11 | - | 9 | - | - | 2 | –3 | –5 | - | - |
Cancer type | Men |
Women |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Least fearful cancer |
Most fearful cancer |
Least fearful cancer |
Most fearful cancer |
|||||||||
Men’s response | Women’s response | p-value |
Men’s response | Women’s response | p-value | Men’s response | Women’s response | p-value | Men’s response | Women’s response | p-value | |
Stomach | 1.24±1.23 | 0.92±1.16 | < 0.001 | 0.45±0.97 | 0.37±0.83 | 0.160 | 0.97±1.16 | 0.94±1.14 | 0.743 | 0.83±1.15 | 0.93±1.15 | 0.185 |
Colon | 0.46±0.93 | 0.36±0.83 | 0.084 | 0.82±1.08 | 0.80±1.07 | 0.760 | 0.24±0.69 | 0.13±0.53 | 0.005 | 0.53±0.97 | 0.42±0.89 | 0.045 |
Lung | 0.21±0.67 | 0.26±0.71 | 0.245 | 1.43±1.27 | 1.41±1.26 | 0.877 | 0.16±0.59 | 0.14±0.54 | 0.724 | 0.82±1.14 | 0.54±0.99 | < 0.001 |
Liver | 0.26±0.70 | 0.29±0.71 | 0.573 | 1.02±1.13 | 0.98±1.10 | 0.609 | 0.10±0.43 | 0.13±0.55 | 0.228 | 0.41±0.84 | 0.35±0.77 | 0.279 |
Thyroid | 1.32±1.25 | 1.09±1.24 | 0.004 | 0.07±0.39 | 0.05±0.38 | 0.367 | 1.98±1.17 | 1.45±1.31 | < 0.001 | 0.06±0.34 | 0.16±0.61 | 0.002 |
Prostate | 1.09±1.16 | 1.26±1.27 | 0.028 | 0.37±0.86 | 0.38±0.91 | 0.782 | - | - | - | - | - | - |
Bladder | 0.46±0.87 | 0.51±0.94 | 0.405 | 0.05±0.30 | 0.07±0.42 | 0.336 | 0.34±0.76 | 0.36±0.78 | 0.704 | 0.05±0.34 | 0.08±0.39 | 0.228 |
Renal | 0.28±0.71 | 0.40±0.84 | 0.014 | 0.13±0.51 | 0.17±0.58 | 0.216 | 0.32±0.79 | 0.27±0.66 | 0.200 | 0.08±0.34 | 0.14±0.53 | 0.017 |
Pancreatic | 0.10±0.43 | 0.18±0.61 | 0.011 | 1.04±1.17 | 0.94±1.18 | 0.170 | 0.08±0.37 | 0.06±0.33 | 0.366 | 0.83±1.17 | 0.57±0.94 | < 0.001 |
Bile duct and gallbladder | 0.35±0.78 | 0.46±0.84 | 0.025 | 0.17±0.56 | 0.22±0.66 | 0.193 | 0.25±0.65 | 0.26±0.71 | 0.799 | 0.11±0.44 | 0.20±0.66 | 0.010 |
Leukemia | 0.17±0.62 | 0.19±0.63 | 0.710 | 0.29±0.77 | 0.34±0.85 | 0.318 | 0.13±0.53 | 0.13±0.55 | 0.965 | 0.44±0.92 | 0.46±0.96 | 0.760 |
Breast | 0.03±0.24 | 0.05±0.32 | 0.214 | 0.20±0.22 | 0.44±0.34 | 0.186 | 0.57±0.94 | 0.85±1.13 | < 0.001 | 0.66±1.07 | 0.82±1.20 | 0.024 |
Cervical | - | - | - | - | - | - | 0.52±0.93 | 0.81±1.12 | < 0.001 | 0.49±0.97 | 0.57±1.03 | 0.207 |
Uterine (endometrial) | - | - | - | - | - | - | 0.29±0.71 | 0.40±0.82 | 0.020 | 0.59±1.01 | 0.64±1.04 | 0.503 |
Ovarian | - | - | - | - | - | - | 0.13±0.49 | 0.26±0.69 | 0.001 | 0.44±0.91 | 0.63±1.05 | 0.002 |
Side effect | Total (rank) | Men (rank) | Women (rank) | Rank difference (men-women) |
---|---|---|---|---|
Pain | 1 | 1 | 1 | 0 |
Fatigue | 5 | 5 | 5 | 0 |
General weakness | 3 | 3 | 3 | 0 |
Digestive dysfunction | 4 | 4 | 4 | 0 |
Sexual dysfunction | 9 | 8 | 11 | –3 |
Psychological problems | 2 | 2 | 2 | 0 |
Urological dysfunction | 10 | 9 | 10 | –1 |
Motor dysfunction | 11 | 11 | 9 | 2 |
Sensory dysfunction | 7 | 10 | 7 | 3 |
Appearance change | 6 | 6 | 6 | 0 |
Lymphedema | 8 | 7 | 8 | –1 |
Infertility | 12 | 12 | 12 | 0 |
Side effect | Men | Women | p-value |
---|---|---|---|
Pain | 2.07±1.20 | 2.10±1.14 | 0.703 |
Fatigue | 0.49±0.90 | 0.57±0.99 | 0.169 |
General weakness | 0.66±0.93 | 0.82±1.01 | 0.011 |
Digestive dysfunction | 0.58±0.91 | 0.65±0.95 | 0.259 |
Sexual dysfunction | 0.23±0.64 | 0.08±0.40 | < 0.001 |
Psychological problems | 0.83±1.08 | 0.85±1.07 | 0.776 |
Urological dysfunction | 0.21±0.66 | 0.09±0.39 | 0.001 |
Motor dysfunction | 0.10±0.44 | 0.09±0.42 | 0.780 |
Sensory dysfunction | 0.16±0.53 | 0.19±0.62 | 0.500 |
Appearance change | 0.41±0.82 | 0.44±0.86 | 0.525 |
Lymphedema | 0.24±0.73 | 0.11±0.45 | 0.001 |
Infertility | 0.01±0.16 | 0.02±0.17 | 0.842 |
Values are presented as number (%). Chi-square test was used.
Values are presented as mean±standard deviation. Student’s t test was used.
Values are presented as mean±standard deviation. Student’s t test was used.